- Home
- GH vs TPG Comparison
GH vs TPG Comparison
Compare GH & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- TPG
- Stock Information
- Founded
- GH 2011
- TPG 1992
- Country
- GH United States
- TPG United States
- Employees
- GH N/A
- TPG N/A
- Industry
- GH Medical Specialities
- TPG Investment Managers
- Sector
- GH Health Care
- TPG Finance
- Exchange
- GH Nasdaq
- TPG Nasdaq
- Market Cap
- GH 5.5B
- TPG 6.6B
- IPO Year
- GH 2018
- TPG 2022
- Fundamental
- Price
- GH $40.62
- TPG $48.13
- Analyst Decision
- GH Strong Buy
- TPG Buy
- Analyst Count
- GH 21
- TPG 12
- Target Price
- GH $52.81
- TPG $62.36
- AVG Volume (30 Days)
- GH 2.3M
- TPG 2.4M
- Earning Date
- GH 04-30-2025
- TPG 05-07-2025
- Dividend Yield
- GH N/A
- TPG 3.62%
- EPS Growth
- GH N/A
- TPG N/A
- EPS
- GH N/A
- TPG N/A
- Revenue
- GH $773,996,000.00
- TPG $3,710,887,000.00
- Revenue This Year
- GH $23.05
- TPG N/A
- Revenue Next Year
- GH $21.40
- TPG $24.30
- P/E Ratio
- GH N/A
- TPG $16,303.55
- Revenue Growth
- GH 28.20
- TPG 44.34
- 52 Week Low
- GH $20.14
- TPG $37.52
- 52 Week High
- GH $52.92
- TPG $72.98
- Technical
- Relative Strength Index (RSI)
- GH 48.45
- TPG 49.12
- Support Level
- GH $37.73
- TPG $47.20
- Resistance Level
- GH $39.63
- TPG $48.53
- Average True Range (ATR)
- GH 1.60
- TPG 1.28
- MACD
- GH -0.01
- TPG -0.30
- Stochastic Oscillator
- GH 60.00
- TPG 24.54
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About TPG TPG Inc.
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.